RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
AIM ImmunoTech Stock

AIM ImmunoTech Revenue 2024

AIM ImmunoTech Revenue

134,663.3 USD

Ticker

AIM

ISIN

US00901B1052

WKN

A2PREX

In 2024, AIM ImmunoTech's sales reached 134,663.3 USD, a -33.33% difference from the 202,000 USD sales recorded in the previous year.

The AIM ImmunoTech Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e118.270,14
2028e51.550,31
2027e9.851,62
2026e3.864,15
2025e1.88,90
2024e0.13118,81
20230.279,21
20220.14100,00
20210.14-529,63
20200.16-394,48
20190.14-537,86
20180.37-140,87
20170.44-170,71
20160.09-1104,35
20150.13-1101,50
20140.2-535,03
20130.15-720,00
20120.21-847,62
20110.16-550,00
20100.14-864,29
20090.11-427,27
20080.27-196,30
20071.0612,26
20060.93-36,56
20051.0863,89
20041.23-71,54

AIM ImmunoTech Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into AIM ImmunoTech, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by AIM ImmunoTech from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects AIM ImmunoTech’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of AIM ImmunoTech. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into AIM ImmunoTech’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing AIM ImmunoTech’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on AIM ImmunoTech’s growth potential.

AIM ImmunoTech Revenue, EBIT and net profit per share

DateAIM ImmunoTech RevenueAIM ImmunoTech EBITAIM ImmunoTech Net Income
2029e118.27 M undefined156.89 M undefined34.05 M undefined
2028e51.55 M undefined-12 M undefined-10.39 M undefined
2027e9.85 M undefined-42.53 M undefined-36.36 M undefined
2026e3.86 M undefined-34.46 M undefined-28.86 M undefined
2025e1.8 M undefined-27.2 M undefined-26.16 M undefined
2024e134,663.3 undefined-24.77 M undefined-24.05 M undefined
2023202,000 undefined-31.92 M undefined-28.96 M undefined
2022141,000 undefined-19.92 M undefined-19.45 M undefined
2021135,000 undefined-17.06 M undefined-19.13 M undefined
2020163,000 undefined-15.02 M undefined-14.4 M undefined
2019140,000 undefined-12.44 M undefined-9.4 M undefined
2018367,000 undefined-11.5 M undefined-9.81 M undefined
2017437,000 undefined-11.42 M undefined-8.26 M undefined
201692,000 undefined-13.8 M undefined-7.5 M undefined
2015133,000 undefined-16.65 M undefined-15.23 M undefined
2014197,000 undefined-19.1 M undefined-17.45 M undefined
2013150,000 undefined-17.17 M undefined-16.23 M undefined
2012210,000 undefined-20.34 M undefined-17.35 M undefined
2011160,000 undefined-14.3 M undefined-9.02 M undefined
2010140,000 undefined-16.39 M undefined-13.14 M undefined
2009110,000 undefined-13.26 M undefined-7.18 M undefined
2008270,000 undefined-12.81 M undefined-12.22 M undefined
20071.06 M undefined-19.29 M undefined-18.14 M undefined
2006930,000 undefined-18.69 M undefined-19.4 M undefined
20051.08 M undefined-9.92 M undefined-12.45 M undefined
20041.23 M undefined-10.89 M undefined-24.14 M undefined

AIM ImmunoTech stock margins

The AIM ImmunoTech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of AIM ImmunoTech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for AIM ImmunoTech.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the AIM ImmunoTech's sales revenue. A higher gross margin percentage indicates that the AIM ImmunoTech retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the AIM ImmunoTech's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the AIM ImmunoTech's total revenue generated. When comparing the revenue margin year over year, investors can gauge the AIM ImmunoTech's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the AIM ImmunoTech. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the AIM ImmunoTech's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

AIM ImmunoTech Margin History

AIM ImmunoTech Gross marginAIM ImmunoTech Profit marginAIM ImmunoTech EBIT marginAIM ImmunoTech Profit margin
2029e79.21 %132.65 %28.79 %
2028e79.21 %-23.28 %-20.15 %
2027e79.21 %-431.88 %-369.19 %
2026e79.21 %-893.32 %-747.94 %
2025e79.21 %-1,513 %-1,455.08 %
2024e79.21 %-18,396.09 %-17,856.84 %
202379.21 %-15,800 %-14,337.62 %
2022100 %-14,129.79 %-13,790.78 %
2021-529.63 %-12,636.3 %-14,168.15 %
2020-394.48 %-9,212.88 %-8,834.36 %
2019-537.86 %-8,887.86 %-6,717.14 %
2018-140.87 %-3,132.43 %-2,673.84 %
2017-170.71 %-2,612.36 %-1,889.93 %
2016-1,104.35 %-15,004.35 %-8,154.35 %
2015-1,101.5 %-12,518.8 %-11,451.13 %
2014-535.03 %-9,694.92 %-8,857.87 %
2013-720 %-11,446.67 %-10,820 %
2012-847.62 %-9,685.72 %-8,261.91 %
2011-550 %-8,937.5 %-5,637.5 %
2010-864.29 %-11,707.14 %-9,385.72 %
2009-427.27 %-12,054.55 %-6,527.27 %
2008-196.3 %-4,744.44 %-4,525.93 %
200712.26 %-1,819.81 %-1,711.32 %
2006-36.56 %-2,009.68 %-2,086.02 %
200563.89 %-918.52 %-1,152.78 %
2004-71.54 %-885.37 %-1,962.6 %

AIM ImmunoTech Aktienanalyse

What does AIM ImmunoTech do?

AIM ImmunoTech Inc is a US-based biotechnology company that focuses on the development of immunotherapeutics and diagnostics for humans and animals. The company has been in operation for over 30 years and specializes in the treatment of viral and autoimmune diseases. AIM ImmunoTech ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding AIM ImmunoTech's Sales Figures

The sales figures of AIM ImmunoTech originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing AIM ImmunoTech’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize AIM ImmunoTech's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in AIM ImmunoTech’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about AIM ImmunoTech stock

How much revenue did AIM ImmunoTech generate this year?

AIM ImmunoTech has achieved a revenue of 134,663.3 USD this year.

How much was the turnover of the company AIM ImmunoTech compared to the previous year?

The revenue of AIM ImmunoTech has increased by -33.33% decreased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of AIM ImmunoTech?

The revenue of AIM ImmunoTech is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of AIM ImmunoTech measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of AIM ImmunoTech so important for investors?

The revenue of AIM ImmunoTech is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does AIM ImmunoTech pay?

Over the past 12 months, AIM ImmunoTech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, AIM ImmunoTech is expected to pay a dividend of 0 USD.

What is the dividend yield of AIM ImmunoTech?

The current dividend yield of AIM ImmunoTech is .

When does AIM ImmunoTech pay dividends?

AIM ImmunoTech pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of AIM ImmunoTech?

AIM ImmunoTech paid dividends every year for the past 0 years.

What is the dividend of AIM ImmunoTech?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is AIM ImmunoTech located?

AIM ImmunoTech is assigned to the 'Health' sector.

Wann musste ich die Aktien von AIM ImmunoTech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of AIM ImmunoTech from 9/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.

When did AIM ImmunoTech pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of AIM ImmunoTech in the year 2023?

In the year 2023, AIM ImmunoTech distributed 0 USD as dividends.

In which currency does AIM ImmunoTech pay out the dividend?

The dividends of AIM ImmunoTech are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von AIM ImmunoTech

Our stock analysis for AIM ImmunoTech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AIM ImmunoTech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.